Paliperidone palmitate - review of the efficacy, safety and cost of a new second-generation depot antipsychotic medication.
about
Changes in body weight and psychotropic drugs: a systematic synthesis of the literatureCharacterization of paliperidone photodegradation products by LC-Q-TOF multistage mass spectrometry.Dose-associated changes in safety and efficacy parameters observed in a 24-week maintenance trial of olanzapine long-acting injection in patients with schizophrenia.Effectiveness of paliperidone palmitate vs haloperidol decanoate for maintenance treatment of schizophrenia: a randomized clinical trialOnce-monthly paliperidone injection for the treatment of schizophreniaLong-acting atypical antipsychotics: characterization of the local tissue responseWorld Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects.Efficacy and safety of once-monthly injection of paliperidone palmitate in hospitalized Asian patients with acute exacerbated schizophrenia: an open-label, prospective, noncomparative study.Paliperidone palmitate and risperidone long-acting injectable in subjects with schizophrenia recently treated with oral risperidone or other oral antipsychotics.Paliperidone Palmitate Treatment in Outpatient Care Setting: A Naturalistic Study.A pooled analysis of injection site-related adverse events in patients with schizophrenia treated with olanzapine long-acting injection.Iloperidone: chemistry, pharmacodynamics, pharmacokinetics and metabolism, clinical efficacy, safety and tolerability, regulatory affairs, and an opinion.Weight gain and changes in metabolic variables following olanzapine treatment in schizophrenia and bipolar disorder.Extended-release intramuscular paliperidone palmitate: a review of its use in the treatment of schizophrenia.A review of paliperidone palmitate.Long-acting injectable formulations of new-generation antipsychotics: a review from a clinical perspective.New second-generation long-acting injectable antipsychotics for the treatment of schizophrenia.Patients' and clinicians' attitude towards long-acting depot antipsychotics in subjects with a first episode of psychosis.Paliperidone for the treatment of schizophrenia and schizoaffective disorders - a drug safety evaluation.Healthcare resource utilization of second-generation long-acting injectable antipsychotics in schizophrenia: risperidone versus paliperidone palmitate.Paliperidone Inducing Concomitantly Syndrome of Inappropriate Antidiuretic Hormone, Neuroleptic Malignant Syndrome, and Rhabdomyolysis.Safety and efficacy of paliperidone palmitate 1-month formulation in Chinese patients with schizophrenia: a 25-week, open-label, multicenter, Phase IV study.Cost-Effectiveness of Long-Acting Injectable Paliperidone Palmitate Versus Haloperidol Decanoate in Maintenance Treatment of Schizophrenia.Incidence and time course of extrapyramidal symptoms with oral and long-acting injectable paliperidone: a posthoc pooled analysis of seven randomized controlled studies.Number needed to treat and number needed to harm with paliperidone palmitate relative to long-acting haloperidol, bromperidol, and fluphenazine decanoate for treatment of patients with schizophreniaPatient perspectives in the development and use of long-acting antipsychotics in schizophrenia: focus on olanzapine long-acting injection.Patient and Health Care Provider Perspectives on Long Acting Injectable Antipsychotics in Schizophrenia and the Introduction of Olanzapine Long-Acting Injection.Paliperidone Palmitate-induced Urinary Incontinence: A Case Report.Clinical improvement, relapse and treatment adherence with paliperidone palmitate 1-month formulation: 1-year treatment in a naturalistic outpatient setting.Injectable Sustained-Release Depots of PLGA Microspheres for Insoluble Drugs Prepared by hot-Melt Extrusion.A randomized trial of paliperidone palmitate and risperidone long-acting injectable in schizophrenia.Pharmacokinetics and tolerability of paliperidone palmitate injection in Chinese subjects.[Advantages and controversies of depot antipsychotics in the treatment of patients with schizophrenia].Long-acting injectable antipsychotics update: lengthening the dosing interval and expanding the diagnostic indications.Impact of time of initiation of once-monthly paliperidone palmitate in hospitalized Asian patients with acute exacerbation of schizophrenia: a post hoc analysis from the PREVAIL study.
P2860
Q28728401-3E0412E8-7A70-4C1B-924E-186586B02513Q33466161-9306C6EB-DACD-473F-852C-9042D3F3F0C2Q33821379-891F534F-6137-425B-B175-15CF90BD0FE4Q33914295-F95924AB-18A5-47D1-A2EB-F77E80127938Q34123015-8CA2183B-0A1E-427E-9969-D5B067B09944Q34130433-88629E11-AFD1-41CE-9D22-AA0EFABF01AFQ34315836-83DBE41C-9EDD-4379-9904-56E8B33BA16AQ36412766-13F2EA60-8188-4D97-8268-554E12B9CF14Q36672952-79003BEF-49E0-4E38-8A47-5BC39BE489FDQ37299914-9C967AB2-0AE2-414D-9C1F-536250E87F41Q37501165-BC3F22F2-DE4A-432A-9567-B582370E25D8Q37804880-348C2B6A-F606-494C-9CD2-33626EB76B47Q37865505-DC13B906-DF68-43C5-BA07-818D0B85D37DQ38008704-A22AAB1F-488A-4797-B9F5-F075DCB5A4F9Q38067137-3DF0E187-2AE3-42CA-8B04-C1D19248E203Q38115487-1FF72A5B-1232-4622-89A2-D559FD613D90Q38125213-FEEC59FF-A40B-4B71-BC79-970A137273D8Q38156171-85300AEA-D241-48DE-89D7-0E9D71BB88E4Q38989642-EDEF7097-211D-462E-B812-868B3B407EE9Q39537859-E09943CC-B110-4D1F-9837-E65A188024AEQ40085873-044A656D-64B7-4F7B-AFD1-9002FC528F30Q41283940-3D81A309-8A46-40B8-B7AA-8DAAF459BD14Q41656775-A80DF927-7B56-4852-8B1F-540F88462870Q41862402-698CA1E2-5674-4EFD-AA37-ECDBD4DD0389Q41997267-FFCD5064-926F-48E2-A705-9194601C2CE8Q42279135-1A938B4E-BB93-4D06-9FC7-8DE64AFF8C9EQ42520005-46648FFE-02A4-4A35-BB7B-CB89F93D4B01Q43063836-F8453DC5-22C3-43C0-977D-AFEC5548927AQ47247292-FED1756F-AE47-4886-AC14-B41C6A5EC546Q47958009-CCB35B68-0353-4899-B6A1-969A6C956247Q48292095-43770ED3-7A4F-4D75-B217-3D802D68E120Q50248080-BD4A3882-FFB0-4455-959B-33B49D925816Q53654663-C1213542-1DD7-419B-82C2-4E8BB89970E6Q54217848-E5A554EF-7F3B-4E34-991D-1C5418CEF88EQ55317641-98019156-BDC4-4569-8E89-10FB942F13B8
P2860
Paliperidone palmitate - review of the efficacy, safety and cost of a new second-generation depot antipsychotic medication.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
Paliperidone palmitate - revie ...... epot antipsychotic medication.
@en
Paliperidone palmitate - revie ...... epot antipsychotic medication.
@nl
type
label
Paliperidone palmitate - revie ...... epot antipsychotic medication.
@en
Paliperidone palmitate - revie ...... epot antipsychotic medication.
@nl
prefLabel
Paliperidone palmitate - revie ...... epot antipsychotic medication.
@en
Paliperidone palmitate - revie ...... epot antipsychotic medication.
@nl
P1476
Paliperidone palmitate - revie ...... epot antipsychotic medication.
@en
P304
P356
10.1111/J.1742-1241.2009.02240.X
P577
2009-11-03T00:00:00Z